Global Non-Invasive Prenatal Testing (NIPT) Market Report 2021: Market to Reach $9.7 Billion by 2027 - U.S. Market is Estimated at $1.2 Billion, While China is Forecast to Grow at 16.1% CAGR - ResearchAndMarkets.com

The "Non-Invasive Prenatal Testing (NIPT) - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Global Non-Invasive Prenatal Testing (NIPT) Market to Reach $9.7 Billion by 2027

Amid the COVID-19 crisis, the global market for Non-Invasive Prenatal Testing (NIPT) estimated at US$4.3 Billion in the year 2020, is projected to reach a revised size of US$9.7 Billion by 2027, growing at a CAGR of 12.2% over the analysis period 2020-2027.

Ultrasound Detection, one of the segments analyzed in the report, is projected to record a 12.5% CAGR and reach US$5.7 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Biochemical Screening Tests segment is readjusted to a revised 11.1% CAGR for the next 7-year period.

The U.S. Market is Estimated at $1.2 Billion, While China is Forecast to Grow at 16.1% CAGR

The Non-Invasive Prenatal Testing (NIPT) market in the U.S. is estimated at US$1.2 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.1 Billion by the year 2027 trailing a CAGR of 16% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.5% and 10.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 9.6% CAGR.

Cell-free DNA in Maternal Plasma Tests Segment to Record 12.8% CAGR

In the global Cell-free DNA in Maternal Plasma Tests segment, USA, Canada, Japan, China and Europe will drive the 12% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$518.7 Million in the year 2020 will reach a projected size of US$1.1 Billion by the close of the analysis period.

China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.4 Billion by the year 2027, while Latin America will expand at a 14.3% CAGR through the analysis period.

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

• Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS (Total 33 Featured):

• Agilent Technologies, Inc.
• Berry Genetics Inc.
• BGI Genomics Co. Ltd.
• Eurofins LifeCodexx GmbH
• F. Hoffmann-La Roche Ltd.
• GE Healthcare
• Igenomix
• Illumina, Inc.
• Laboratory Corporation of America Holdings
• Natera, Inc.
• PerkinElmer Inc.
• Thermo Fisher Scientific Inc.
• Yourgene Health

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

• UNITED STATES
• CANADA
• JAPAN
• CHINA
• EUROPE
• FRANCE
• GERMANY
• ITALY
• UNITED KINGDOM
• SPAIN
• RUSSIA
• REST OF EUROPE
• ASIA-PACIFIC
• AUSTRALIA
• INDIA
• SOUTH KOREA
• REST OF ASIA-PACIFIC
• LATIN AMERICA
• ARGENTINA
• BRAZIL
• MEXICO
• REST OF LATIN AMERICA
• MIDDLE EAST
• IRAN
• ISRAEL
• SAUDI ARABIA
• UNITED ARAB EMIRATES
• REST OF MIDDLE EAST
• AFRICA

IV. COMPETITION

• Total Companies Profiled: 33

For more information about this report visit https://www.researchandmarkets.com/r/fz7z28